Prism.bio is proud to announce its acceptance into the latest cohort of the Merck Digital Sciences Studio (MDS Studio), a digital accelerator designed to enable the next generation of technologies for drug discovery and development, including artificial intelligence and machine learning. MDS Studio was founded to offer support for early-stage biomedical startups providing strategic guidance, direct investment, and connection opportunties within Merck.

About Merck Digital Sciences Studio

The Merck Digital Sciences Studio (MDS Studio or MDSS), a collaboration between Merck, Merck Global Health Innovation Fund, Northpond Ventures, McKesson Ventures, Microsoft for Startups, and the New Jersey Innovation Institute, a New Jersey Institute of Technology (NJIT) subsidiary. The 10-month startup accelerator program, with direct investments from Merck Global Health Innovation Fund, Northpond Ventures, and McKesson Ventures, empowers members and enables the generation of innovative digital technologies for drug discovery and development through hands-on mentorship, connection opportunities with industry-leading partners, and training in an active entrepreneurial setting. Through the accelerator program, these startups will have access to workshops, coaching, office space, and Microsoft for Startups Founders Hub resources, including up to $150,000 Azure Cloud computing credits.